Michael Jansen, MD
Ophthalmology · Denver, CONPI 1265878466
Payments from drug & device makers
Across 451 payments — averaging $3936.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$1.7M
- Astellas Pharma US Inc$35K
- AbbVie$13K
- Apellis Pharmaceuticals, Inc.$8K
- Genentech USA, Inc.$7K
- Alimera Sciences, Inc.$2K
- plus $7K from 24 others
Across 1 payment — averaging $10,277 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$10K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ocular Therapeutix, Inc. | 193 | $1,703,285 |
| Astellas Pharma US Inc | 51 | $35,260 |
| AbbVie(2 entities) | 41 | $12,990 |
| Apellis Pharmaceuticals, Inc. | 17 | $7,664 |
| Genentech USA, Inc. | 33 | $7,252 |
| Alimera Sciences, Inc. | 17 | $2,266 |
| Regeneron Healthcare Solutions, Inc. | 20 | $1,277 |
| Regeneron | 5 | $931 |
| Optos, Inc. | 7 | $635 |
| Novartis | 5 | $573 |
| Dutch Ophthalmic, USA | 6 | $542 |
| Bausch & Lomb Americas Inc. | 4 | $402 |
| Mallinckrodt Hospital Products Inc. | 9 | $354 |
| Oculus Surgical Inc. | 3 | $294 |
| Mallinckrodt Enterprises LLC | 2 | $251 |
| Carl Zeiss Meditec, Inc. | 2 | $227 |
| Genentech, Inc. | 2 | $200 |
| Topcon Healthcare, Inc. | 1 | $153 |
| Biogen | 7 | $138 |
| ANI Pharmaceuticals, Inc. | 6 | $135 |
| Eyepoint US, Inc. | 1 | $125 |
| Neurotech Pharmaceuticals, Inc. | 3 | $123 |
| Harrow Eye, LLC | 5 | $101 |
| Coherus Oncology, Inc. | 4 | $78 |
| Carl Zeiss Meditec USA, Inc. | 1 | $50 |
| Biotissue Holdings Inc. | 1 | $47 |
| Alcon | 2 | $42 |
| Aerie Pharmaceuticals, Inc. | 1 | $22 |
| Astellas Pharma Global Development | 1 | $22 |
| Cardinal Health 108 LLC | 1 | $17 |
How this compares
$1,775,456 in reported general payments places this provider in the 95th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Denver
- Curtis HagedornDenver$1.5M
- Cristos IfantidesDenver$1.4M
- Mark DaceyDenver$798K
- Peter HovlandDenver$568K
- Kingsley OkaforDenver$317K
- Jack ZamoraDenver$172K
- Eva KimDenver$95K
- Michael SolomonDenver$12K
- Matthew KrugerDenver$8K
- Stuart LewisDenver$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.